XML 90 R75.htm IDEA: XBRL DOCUMENT v3.8.0.1
Liabilities Measured at Fair Value Using Level 3 Inputs (Detail) - Contingent Payment
$ in Thousands
12 Months Ended
Dec. 31, 2017
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Contingent acquisition consideration payable, Beginning balance $ 161,637
Changes in the fair value of other contingent acquisition consideration payable 14,587
Foreign exchange remeasurement of Euro denominated contingent acquisition consideration payable 20,487
Contingent acquisition consideration payable, Ending balance 188,966
Huxley Pharmaceuticals, Inc.  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Milestone payments to former shareholders (3,500)
Firdapse  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Reversal of contingent liability related to revised estimate of Firdapse FDA acceptance and approval milestones $ (4,245)